Related Experiment Videos

Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children

Lisa R McDonald1, Colleen H McCarthy

  • 1University of Texas M.D. Anderson Cancer Center, Houston, USA. lrmcdona@mdanderson.org

Clinical Journal of Oncology Nursing
|December 30, 2006
PubMed

Insights

Pediatric leukemia, particularly acute lymphoblastic leukemia, affects thousands of children annually. Many children do not respond to current treatments, highlighting an urgent need for improved therapies.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Research

Background:

  • Leukemia accounts for 30% of childhood cancer diagnoses annually.
  • Acute lymphoblastic leukemia is the most common pediatric leukemia, representing 80% of cases.
  • Many children with leukemia exhibit resistance to chemotherapy or relapse after treatment, indicating a critical unmet medical need.

Purpose of the Study:

  • To address the poor prognosis and limited treatment options for pediatric leukemia patients.
  • To explore novel therapeutic strategies for acute lymphoblastic leukemia.
  • To improve long-term survival rates in children diagnosed with leukemia.

Main Methods:

  • This study focuses on the challenges in treating pediatric leukemia.
  • It reviews current treatment failures and survival outcomes.
  • Further details on specific methodologies are pending.

Main Results:

  • A significant proportion of children with leukemia do not respond to standard chemotherapy.
  • Relapse rates remain high, leading to poor long-term survival.
  • Existing treatments are insufficient for a substantial number of pediatric leukemia cases.

Conclusions:

  • There is a critical need for innovative and effective treatments for pediatric leukemia.
  • Current therapeutic approaches require significant improvement to enhance patient outcomes.
  • Further research is essential to develop better strategies for combating childhood leukemia.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...